Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AMG 706

Known as: AMG-706, AMG706 
An orally bioavailable multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits… Expand
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Imetelstatmotesanib diphosphate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell…
Purpose This phase III, randomized, placebo-controlled, double-blind study determined whether motesanib improved progression-free… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
2014
2014
Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.
Cancer cells often become resistant to chemotherapy through a phenomenon known as multidrug resistance (MDR). Several factors are… Expand
2013
2013
Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?
Medullary thyroid carcinoma (MTC), a rare malignancy arising from the parafollicular C cells of the thyroid gland, accounts for… Expand
  • table 1
Review
2012
Review
2012
The expanding role of somatostatin analogs in the management of neuroendocrine tumors.
  • E. Wolin
  • Gastrointestinal cancer research : GCR
  • 2012
    • Corpus ID: 42865288
BACKGROUND Neuroendocrine tumors (NETs) are neoplasms arising most often in the GI tract, pancreas, or lung. Diagnosis of NETs is… Expand
2009
2009
Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma
[1] ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the… Expand
Highly Cited
2007
Highly Cited
2007
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
PURPOSE AMG 706 is an investigational, orally bioavailable inhibitor of vascular endothelial growth factor receptors 1, 2, and 3… Expand
Highly Cited
2006
Highly Cited
2006
AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces…
The growth of solid tumors is dependent on the continued stimulation of endothelial cell proliferation and migration resulting in… Expand
  • table 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2006
Review
2006
Epidermal Growth Factor Receptor–Mediated Signal Transduction in the Development and Therapy of Gliomas
The epidermal growth factor receptor (EGFR) and its ligands figure prominently in the biology of gliomas, the most common tumors… Expand
  • table 1
  • table 2
  • figure 2
  • table 3
2006
2006
Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC).
7119 Introduction: AMG 706 is an investigational, oral, multi-kinase inhibitor with both antiangiogenic and direct antitumor… Expand
2006
2006
Safety and antitumor activity of AMG 706 in patients (pts) with thyroid cancer (TC): A subset analysis from a phase 1 dose-finding study.
3030 Background: AMG 706 is an investigational, oral, small molecule multi-kinase inhibitor with both antiangiogenic and direct… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE